Strs Ohio bought a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 17,700 shares of the company's stock, valued at approximately $587,000.
Several other large investors also recently bought and sold shares of HRMY. Financial Management Professionals Inc. acquired a new stake in Harmony Biosciences during the 1st quarter valued at approximately $29,000. Brooklyn Investment Group lifted its stake in Harmony Biosciences by 1,031.9% during the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock valued at $35,000 after acquiring an additional 970 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Harmony Biosciences during the 4th quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in Harmony Biosciences during the 1st quarter valued at approximately $57,000. Finally, CWM LLC lifted its stake in Harmony Biosciences by 34.8% during the 1st quarter. CWM LLC now owns 2,704 shares of the company's stock valued at $90,000 after acquiring an additional 698 shares during the period. Hedge funds and other institutional investors own 86.23% of the company's stock.
Harmony Biosciences Stock Down 1.9%
Shares of HRMY stock traded down $0.61 on Tuesday, hitting $31.81. 201,903 shares of the stock were exchanged, compared to its average volume of 665,453. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $1.83 billion, a P/E ratio of 10.27, a price-to-earnings-growth ratio of 0.38 and a beta of 0.84. The business has a 50-day moving average of $35.49 and a 200 day moving average of $33.52. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The company had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. During the same period last year, the company posted $1.05 earnings per share. The business's revenue for the quarter was up 16.0% on a year-over-year basis. Harmony Biosciences has set its FY 2025 guidance at EPS. Equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages have commented on HRMY. Truist Financial initiated coverage on shares of Harmony Biosciences in a research note on Monday, July 21st. They set a "buy" rating and a $48.00 price objective for the company. The Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a research note on Thursday, July 10th. They issued a "neutral" rating and a $33.00 target price for the company. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $55.00 target price (up from $54.00) on shares of Harmony Biosciences in a research note on Thursday, July 10th. Wall Street Zen upgraded shares of Harmony Biosciences from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Oppenheimer initiated coverage on shares of Harmony Biosciences in a research note on Monday, June 2nd. They issued an "outperform" rating and a $61.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Harmony Biosciences has a consensus rating of "Buy" and a consensus target price of $51.00.
Get Our Latest Report on HRMY
Harmony Biosciences Company Profile
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
See Also
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
